Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today announced a ... Spherix Incorporated v. Verizon Services Corp. et al. , ... for the Eastern District of Virginia ... 1, 2015 interpreting certain key claims in favor of ...
(Date:7/1/2015)... and PARIS , July ... and Genective, key developer of biotech crops, today ... of new generations of insect control traits. ... to counter the realities of advancing insect resistance. ... AgBiome,s unique insect control technology with Genective,s capability ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... STRATFORD, CONNECTICUT (PRWEB) , ... July 01, 2015 ... ... disinfected or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have ... of medical devices now have an operator control device that will increase healthcare ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... XI,AN, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- China ... announced that management will be,participating in the ... Grand Hyatt Hotel in Beijing. Management,s participation ... September 10, 2008 at 9:45 a.m.,local time ...
... WALTHAM, Mass., Sept. 4 Repligen Corporation,(Nasdaq: ... received $1.125 million,in research grants to support the ... are comprised of $1 million from the,Muscular Dystrophy ... Foundation (FARA) and the National Ataxia Foundation (NAF).,The ...
... LOUIS, Sept. 4 SAFC Hitech(TM), a focus,area ... (Nasdaq: SIAL ),today announced that it has ... or GST) precursors for use in,high volume manufacturing ... been conducted with both the precursors and with ...
Cached Biology Technology:China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit 2Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 2Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 3Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 4Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 5SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications 2SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications 3SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications 4
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... How,s this for precision? Researchers with the University of ... knock single atoms off a silicon wafer without disturbing ... engineering professor Vince Donnelly and Demetre Economou, Hugh Roy ... same department, are supported in this project by an ...
... to share knowledge, projects and developments in ... creation of synergies and possible frameworks for ... and institutions that address this matter. ... and will be open untill November 11th., ...
... at the National Science Foundation (NSF)--working cooperatively with ... field science supported by the U.S. Antarctic Program, ... to the maximum extent possible, following the October ... a Presidential mandate to manage the U.S. Antarctic ...
Cached Biology News:Creating smaller, and more powerful, integrated circuits 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 3
... A modified nucleotide structure called ... 5?-end of most naturally-occurring eukaryotic mRNAs ... Cap Analog for a portion of ... vitro transcription reaction results in the ...
... Forma Stacking Orbital Shakers ... at top speed stacked 3-high, ... control for sensitive "soft shake" ... proven components and systems, our ...
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
Biology Products: